High-purity Ipamorelin and CJC-1295 co-formulations represent a cornerstone in somatotropic research, enabling investigators to evaluate dual-receptor signaling in preclinical models. PX1 Research supplies USA-manufactured peptide blends verified by lot-specific RP-HPLC and mass spectrometry. Every vial is batch-tested for purity and endotoxin compliance to ensure maximum reproducibility across in vitro and animal studies.
High-purity Ipamorelin and CJC-1295 co-formulations represent a cornerstone in somatotropic research, enabling investigators to evaluate dual-receptor signaling in preclinical models. PX1 Research supplies USA-manufactured peptide blends verified by lot-specific RP-HPLC and mass spectrometry. Every vial is batch-tested for purity and endotoxin compliance to ensure maximum reproducibility across in vitro and animal studies.
When seeking to buy ipamorelin cjc-1295 blend reagents for laboratory research, qualified investigators require verifiable chemical identity, ultra-high purity (>99%), and batch-specific documentation. PX1 Research provides USA-manufactured, lyophilized Ipamorelin and CJC-1295 co-formulations verified via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and Electrospray Ionization Mass Spectrometry (ESI-MS). Each lot includes a downloadable Certificate of Analysis confirming sequence integrity, exact mass, and low endotoxin levels for reliable preclinical experimentation.
The combination of Ipamorelin and CJC-1295 is widely studied in experimental endocrinology because it targets two distinct receptor pathways controlling growth hormone (GH) transcription and release. By providing both compounds in precise molar ratios within a single analytical-grade vial, researchers can eliminate preparation variability, reduce reconstitution errors, and maintain strict protocol consistency across longitudinal in vitro and animal models.
To understand the experimental utility of this blend, investigators analyze the complementary mechanisms of its constituent peptides. CJC-1295 functions as a synthetic GHRH analog, while Ipamorelin operates as a selective growth hormone secretagogue receptor (GHSR-1a) agonist. In physiological systems, endogenous GH secretion is regulated via the simultaneous action of growth hormone-releasing hormone (GHRH) and ghrelin. Combining their synthetic counterparts in preclinical models mimics this dual-input mechanism, resulting in a synergistic amplification of somatotrope activity.
Preclinical studies suggest that co-administration of a GHRH receptor agonist with a GHSR-1a agonist yields a significantly greater growth hormone release than the mathematical sum of either compound administered in isolation. This non-linear secretagogue response allows researchers to explore maximal receptor occupancy, intracellular cyclic adenosine monophosphate (cAMP) accumulation, and downstream endocrine signaling with high precision.
CJC-1295 is a 29-amino-acid tetrasubstituted peptide derivative of human GHRH (1-29) amide. Studied as a long-acting growth-hormone-releasing hormone, CJC-1295 sustains GH and downstream IGF-1 levels for tissue repair research by maintaining structural resistance against enzymatic cleavage. Naturally occurring GHRH is rapidly degraded in blood plasma by dipeptidyl peptidase IV (DPP-IV). By replacing specific amino acid residues at positions 2, 8, 15, and 27, CJC-1295 demonstrates enhanced enzymatic stability and extended half-life in laboratory models.
Upon binding to the GHRH receptor on anterior pituitary somatotropes, CJC-1295 No DAC activates the G-protein-coupled receptor cascade, stimulating adenylate cyclase and increasing intracellular cAMP levels. This downstream signaling cascade promotes gene expression of growth hormone and facilitates its storage in secretory vesicles. In preclinical models, sustained GHRH receptor stimulation translates to elevated baseline expression of insulin-like growth factor 1 (IGF-1), providing a stable model for studying cellular regeneration, protein synthesis, and extracellular matrix remodeling.
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2Nal-D-Phe-Lys-NH2) engineered to selectively target the ghrelin receptor (GHSR-1a). Unlike early-generation growth hormone secretagogues, Ipamorelin exhibits remarkable receptor selectivity. In vitro binding assays demonstrate that Ipamorelin binds GHSR-1a with high affinity, triggering intracellular calcium influx via the phospholipase C (PLC) and inositol trisphosphate (IP3) pathways without cross-reacting with adjacent neuroendocrine receptors.
A primary advantage of utilizing Ipamorelin in laboratory research is its minimal effect on off-target hormones. In vivo animal models confirm that Ipamorelin administration stimulates pulsatile growth hormone secretion without causing significant elevations in plasma cortisol, adrenocorticotropic hormone (ACTH), or prolactin. This selectivity allows researchers to isolate somatotropic pathways without confounding variables stemming from stress-axis or lactotropic activation.
Co-formulated Ipamorelin and CJC-1295 are frequently deployed in animal models of musculoskeletal damage, wound healing, and metabolic dysregulation. Preclinical studies suggest that dual somatotropic stimulation accelerates extracellular matrix deposition and collagen synthesis in damaged connective tissues. In rodent models of Achilles tendon injury and osteotomy repair, elevated systemic GH and IGF-1 driven by GHRH and GHSR activation correlated with increased tensile strength and accelerated bone mineral density recovery.
Additionally, investigators utilize the blend to study metabolic signaling, nitrogen retention, and lipid metabolism. In vitro adipocyte cultures and animal models of catabolism indicate that combined secretagogue administration enhances lipolysis via beta-3 adrenergic receptor upregulation while simultaneously promoting amino acid uptake in skeletal muscle tissue. These findings position the blend as an important tool for investigating sarcopenia, metabolic rate regulation, and cellular longevity signaling.
When designing preclinical protocols, researchers often evaluate the Ipamorelin CJC-1295 blend against individual secretagogues or alternative peptide combinations. For example, comparing the blend to single-agent Sermorelin reveals key differences in half-life and receptor kinetics; while Sermorelin offers short-acting GHRH receptor stimulation, CJC-1295 provides prolonged receptor occupancy. Furthermore, comparing Ipamorelin to broader-spectrum secretagogues like GHRP-6 highlights Ipamorelin's superior target selectivity, as GHRP-6 frequently induces appetite-stimulating hypothalamic signaling and cortisol release.
Another candidate frequently referenced in somatotropic research is Tesamorelin, a stabilized GHRH analog with specific activity in visceral adipose tissue models. While Tesamorelin acts solely through the GHRH pathway, the Ipamorelin CJC-1295 blend engages both GHRH and GHSR-1a targets simultaneously. This dual-pathway activation routinely yields higher total GH area-under-the-curve (AUC) measurements in preclinical assays, making the blend preferred for studies requiring maximal GH pulse amplitude alongside sustained IGF-1 elevation.
PX1 Research supplies the Ipamorelin CJC-1295 blend as a sterile, lyophilized cake inside sealed borosilicate glass vials. Lyophilization ensures long-term chemical stability during transport and storage. Upon receipt, sealed vials should be stored in a commercial freezer at -20°C or -80°C, protected from light and moisture. Under these conditions, the un-reconstituted peptide complex maintains integrity for up to 24 months.
For laboratory experiment setup, reconstitution must be performed under a laminar flow hood using sterile laboratory diluents such as bacteriostatic water (0.9% benzyl alcohol) or sterile normal saline (0.9% NaCl). Gentle side-wall injection followed by smooth swirl rotation is recommended to dissolve the lyophilized powder completely. Mechanical agitation, vortexing, or high-shear mixing must be avoided, as physical stress can denature delicate peptide secondary structures. Reconstituted solutions should be stored at 2°C to 8°C and utilized within 30 days to prevent hydrolytic degradation.
In modern peptide research, analytical transparency is non-negotiable. Substandard reagents containing residual solvents, TFA salts, or truncated synthesis sequences introduce unaccounted variables that compromise experimental validity. When researchers buy ipamorelin cjc-1295 blend from PX1 Research, they receive materials processed in ISO 17025 accredited analytical laboratories operating within GMP-compliant synthesis facilities.
Every batch undergoes rigorous quality assurance protocols:
• Reverse-Phase HPLC (RP-HPLC): Establishes chemical purity levels exceeding 99.0%, identifying and quantifying potential minor impurities or related substances. • Mass Spectrometry (ESI-MS): Verifies exact molecular mass matching the theoretical molecular weight of both Ipamorelin and CJC-1295. • Limulus Amebocyte Lysate (LAL) Testing: Quantifies bacterial endotoxin levels to ensure compliance with strict laboratory limits (<0.01 EU/mg), preventing non-specific inflammatory responses in cellular assays. • Residual Solvent & Heavy Metal Screening: Confirms the complete removal of organic synthesis reagents such as piperidine, DMF, and TFA.
PX1 Research serves as a trusted domestic supply partner for academic institutions, biotechnology firms, and independent research facilities across North America. All orders are processed rapidly from our primary logistics hubs in California and Arizona, with same-day shipping offered Monday through Friday for orders placed before standard daily cutoffs.
To explore our complete portfolio of growth factor modulators, secretagogues, and custom synthesis options, visit our comprehensive all research peptides catalog. Academic laboratories and high-volume institutions requiring bulk quantities can apply for specialized pricing structures through our wholesale research accounts portal. To review mechanistic literature and scientific whitepapers, explore the PX1 peptide research hub.
What is the rationale for combining Ipamorelin and CJC-1295 in a single research formulation?
Combining Ipamorelin and CJC-1295 allows investigators to simultaneously stimulate the GHSR-1a ghrelin receptor and the GHRH receptor. In preclinical models, co-activation produces a synergistic release of growth hormone that exceeds the additive effects of either peptide administered alone.
How is CJC-1295 categorized in terms of mechanism?
CJC-1295 is a synthetic GHRH analog. It is studied as a long-acting growth-hormone-releasing hormone that sustains growth hormone and downstream IGF-1 levels for tissue repair and metabolic research.
What analytical methods are used to verify the purity of PX1 Research peptide blends?
PX1 Research verifies every lot using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity determination and Electrospray Ionization Mass Spectrometry (ESI-MS) for molecular mass confirmation. Endotoxin levels are measured via LAL testing.
What is the recommended storage temperature for lyophilized peptide blends?
Unopened, lyophilized vials should be stored at -20°C to -80°C in a dry, dark environment to ensure maximum stability. Once reconstituted, solutions should be kept refrigerated at 2°C to 8°C.
Does Ipamorelin alter cortisol or prolactin levels in research models?
In vitro and animal models demonstrate that Ipamorelin is highly selective for GHSR-1a and does not significantly alter plasma cortisol, ACTH, or prolactin concentrations, unlike older GHRP compounds.
How does CJC-1295 No DAC differ from CJC-1295 DAC?
CJC-1295 No DAC (Modified GRF 1-29) lacks the Drug Affinity Complex (DAC) reactive group, resulting in a shorter half-life that mimics physiological pulsatile GHRH release rather than continuous, prolonged binding.
Are PX1 Research products intended for clinical or veterinary use?
No. All products sold by PX1 Research are strictly for laboratory research use only, including in vitro assays and controlled preclinical animal studies. They are not for human or clinical consumption.
What are the standard shipping timelines for PX1 Research orders?
PX1 Research ships orders same-day Monday through Friday from facilities located in California and Arizona, offering fast standard and expedited delivery options to minimize research delays.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.